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In this issue ofNeuron, Foster et al. (2015) show that ablating, silencing, or activating spinal glycinergic inhib-
itory neurons with viral vectors all have dramatic effects on pain and itch. These results provide molecular
insights into pain gate control and useful tools for the rapid analysis of other CNS circuits.Gasser (1941), who had been measuring
action potential velocities in peripheral
nerves, demonstrated that there were
fast and slower fibers that could both
produce a sensation of pain. He also
observed, ‘‘it (slow pain) can be relieved
by rubbing the spot, that is, it may be
inhibited by sending into the central ner-
vous system a flood of impulses carried
in rapidly conducting fibers.’’
This observation was the precursor
of the gate control theory expounded
by Melzack and Wall 50 years ago in
Science, which has had a profound influ-
ence on the development of ideas about
peripheral pain mechanisms and their
central regulation. Simply put, the theory
states that innocuous sensation can
drive inhibitory circuits that tonically block
potentially painful input into the dorsal
horn of the spinal cord (Melzack and Wall,
1965). Although the original gate control
proposals have been modified many
times over the years (Mendell, 2014), the
present paper by the Zeilhofer group
provides a magisterial cell and molecular
analysis of the role of glycinergic inhibi-
tory neurons of the spinal cord in gating
noxious input, and demonstrates that
the gate control concept remains impor-
tant and relevant to understanding pain -
mechanisms (Figure 1). Perhaps as impor-
tantly, these studies describe broadly
applicable rapid approaches to the
analysis of neuronal circuitry using AAV
virus-mediated transduction to activate,
silence, or kill Cre-expressing neurons.
Inhibitory neurons in the spinal cord
release GABA, glycine, or both neuro-
transmitters. A great deal of evidence
that spinal inhibitory circuits play a key
role in regulating pain perception in dis-
ease states has been reviewed recently
(Zeilhofer et al., 2012). In the present
study, Foster et al. (2015) generated a1152 Neuron 85, March 18, 2015 ª2015 Elsemouse expressing a BAC-Cre driven by
the neuronal glycine transporter GlyT2
promoter and examined the pattern of
expression of recombinase activity. Using
Lac-Z reporters together with GFP pre-
sent in GlyT2-positive neurons, an excel-
lent match of functional Cre expression
was found in spinal cord neuronal popula-
tions, predominantly in the deep dorsal
horn.
Having genetically defined spinal cord
glycinergic neurons, a range of AAV
and rabies viruses were generated that
exploit the FLEX system to tightly control
Cre-dependent cell type-specific expres-
sion (Atasoy et al., 2008). The first ques-
tion addressed was, what cells innervate
the deep dorsal horn glycinergic neurons?
A recently developed virus-mapping
strategy was employed (Wickersham
et al., 2007). Defective rabies virus coding
for eGFP and pseudotyped with the
avian sarcoma/leukosis virus envA glyco-
protein was used to infect only glycinergic
neurons. This selective infection of
glycinergic neurons was made possible
through an earlier injection of an AAV
vector that expresses the avian envA
binding receptor TVA in a Cre-dependent
manner. The competent rabies virus was
then observed in GFP+ neurons in the
spinal cord, and progressed to neuronal
cell bodies in adjacent dorsal root
ganglion neurons that were typed with
immunocytochemical markers to show
they were myelinated and had properties
consistent with a non–nociceptive role.
In other words, inhibitory neurons in the
spinal cord are indeed innervated by
non-nociceptive presumptive touch-sen-
sitive myelinated neurons consistent with
gate control theory and Gasser’s early
observations. Other inputs to glycinergic
neurons from supraspinal sites may also
contribute to inhibitory activity, but thisvier Inc.aspect was not addressed in the present
study.
Next, the role of glycinergic neurons
was investigated by cell ablation using
diphtheria toxin or by neural silencing
with tetanus toxin using AAV virus to
deliver the toxins. Both approaches
provided consistent data. As microglial
activation is much more pronounced
with cell death, rather than silencing, a
critical role for microglia in regulating
pain in these experiments could be ruled
out. Diphtheria toxin delivery led to the
loss of substantial numbers of deep
dorsal horn inhibitory neurons as well as
almost one-fifth of inhibitory neurons in
laminae 1 or 2 where 80% of inhibitory
neurons are GlyT2 negative.
What neurons are targeted by the
GlyT2-Cre positive neurons? The conse-
quence of GlyT2+ cell loss on inhibitory
input into laminae 1 and 2 neurons was
investigated optogenetically in spinal
cord slices, where cell ablation caused
more than 50% diminution of inhibitory
postsynaptic currents in presumptive
excitatory dorsal horn neurons. Here,
channelrhodopsin was expressed in
both GABAergic and glycinergic neurons
using a vGAT promoter, while only the
GlyT2 subset was ablated with diphtheria
toxin. About 70% of the inhibitory input
is blocked by strychnine supporting an
important role for glycine in inhibitory
input to dorsal horn neurons. A high level
of expression of the glycine receptor
GlyRa3 is observed in the superficial
laminae of the spinal cord where GlyT2+
fibers are also observed. These obser-
vations fit with some aspects of the
Melzack andWall model in demonstrating
a circuit that links innocuous input to
inhibitory neurons that subsequently syn-
apse on dorsal horn neurons receiving
nociceptive input. Whether there may
Figure 1. How Glycinergic Interneurons Mediate Gate Control of Pain Pathways in the Spinal Cord
Gasser (left) articulated the role of low-threshold mechanoreceptors in pain control in his Nobel Prize-winning studies of peripheral neuron excitability. Amodel of
gate control theory by Melzack and Wall (center) was published 50 years ago in Science. In the present issue, Zeilhofer (right) and collaborators show the
role of glycinergic neurons in controlling nociceptive input leading to sensations of pain and itch. The cartoon demonstrates the functional consequences of
manipulating glycinergic inhibition on dorsal horn neurons involved in pain circuitry.
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tive input to the dorsal horn, an aspect
of the original model, was not examined,
but the significance of glycinergic inhibi-
tion on second-order sensory neurons
thus seems clear.Next, the behavioral consequences of
manipulating GlyT2+ neuronal activity
were assessed in classical pain tests for
mechanical, heat, and cold sensation.
Within 1–2 days, cell ablation with AAV-
flex-diphtheria toxin lead to sensitizationNeuron 85of withdrawal responses to von Frey fila-
ments, heating with a Hargreaves appa-
ratus, and cold withdrawal with minimal
effects on motor behavior. Signs of spon-
taneous discomfort were also apparent
in terms of flinching and limb guarding., March 18, 2015 ª2015 Elsevier Inc. 1153
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in these studies was the spontaneous
reversal of ongoing pain activity with
time in mice where glycinergic input was
lowered. The mechanistic basis of this
interesting effect remains mysterious,
but C-fos expression in the dorsal horn
mirrored the pain both in terms of its
development and partial resolution, sug-
gesting that plasticity in the spinal cord
plays a role. Tetanus toxin-mediated
silencing of GlyT2 cells gave effectively
similar results to cell ablation.
Can exogenous activation of the GlyT2
cells produce useful analgesia? This
question was addressed by delivering
a modified muscarinic GPCR that is
activated by the compound clozapine-N-
oxide (CNO) to drive neuronal activity
(Alexander et al., 2009). This Gq- and
PLC-coupled receptor probably acts
through regulation of potassium channels
to enhance neuronal excitability. Acute
pain thresholds were blunted with the
increased inhibitory activity of GlyT2 neu-
rons upon administration of CNO. More
importantly, after a chronic constriction
injury leading to mechanical allodynia,
CNO reversed the sensitization within a
few hours. Itching caused by pruritogens
such as histamine was also reversed,
demonstrating a role for glycinergic
inhibition in the control of itch circuitry.
Thus, spontaneous pain, neuropathic
pain, and itch all can be inhibited by acti-
vating spinal GlyT2+ glycinergic neurons.
These observations raise a number
of questions. If innocuous A-beta fiber1154 Neuron 85, March 18, 2015 ª2015 Elseactivation is able to maximally activate
glycinergic inhibition of nociceptive input,
then should a good rub be an effective
treatment for neuropathic pain or itch? It
certainly seems to be useful for acute
pain. If, however, innocuous sensation
normally keeps nociceptor input close to
the threshold for the induction of pain,
as seems to be the case, one has to ask,
what are the physiological advantages of
such a system? One possibility is that
innocuous input is as important as dam-
age sensing in terms of organismal func-
tion and survival. Deficits in innocuous
sensation might then lead to pain through
the loss of glycinergic inhibition and
cause subtle modifications in behavior
to redress the loss of innocuous input
(e.g., stretching or other movements).
In summary, the present study adds cell
and molecular detail to a gate control
model of spinal pain control that rein-
forces the importance of glycinergic
inhibitory circuits in the control of pain.
Whether this information will provide a
route to clinically useful pharmacological
control of chronic pain remains to be
tested. However, the exploitation of
AAV viruses in conjunction with mice
expressing Cre-recombinase to map cir-
cuits with rabies virus, silence cells with
tetanus toxin, kill cells with diphtheria
toxin, or activate them optogenetically or
pharmacologically provides experimental
paradigms and reagents that should be
useful for a myriad of questions about
brain function. Dramatic advances in
single-cell RNAseq technology (Usoskinvier Inc.et al., 2015) and combinatorial genetics
(Yang et al., 2013) that help define distinct
neuronal subsets, combined with the
technology described by Zeilhofer’s
team, suggest that we have now entered
an exciting new period of genetic insight
into mammalian neuronal circuitry, sensa-
tion, and behavior.REFERENCES
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